EA200000449A1 - Модифицированные витамины к-зависимые полипептиды - Google Patents

Модифицированные витамины к-зависимые полипептиды

Info

Publication number
EA200000449A1
EA200000449A1 EA200000449A EA200000449A EA200000449A1 EA 200000449 A1 EA200000449 A1 EA 200000449A1 EA 200000449 A EA200000449 A EA 200000449A EA 200000449 A EA200000449 A EA 200000449A EA 200000449 A1 EA200000449 A1 EA 200000449A1
Authority
EA
Eurasian Patent Office
Prior art keywords
dependent polypeptides
polypeptides
mammals
modified vitamins
formation
Prior art date
Application number
EA200000449A
Other languages
English (en)
Inventor
Гэри Л. Нелсестюен
Original Assignee
Риджентс Оф Дзе Юниверсити Оф Миннесота
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Риджентс Оф Дзе Юниверсити Оф Миннесота filed Critical Риджентс Оф Дзе Юниверсити Оф Миннесота
Publication of EA200000449A1 publication Critical patent/EA200000449A1/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/52—Genes encoding for enzymes or proenzymes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6424—Serine endopeptidases (3.4.21)
    • C12N9/6437—Coagulation factor VIIa (3.4.21.21)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6424—Serine endopeptidases (3.4.21)
    • C12N9/644—Coagulation factor IXa (3.4.21.22)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6424—Serine endopeptidases (3.4.21)
    • C12N9/6464—Protein C (3.4.21.69)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6424—Serine endopeptidases (3.4.21)
    • C12N9/647—Blood coagulation factors not provided for in a preceding group or according to more than one of the proceeding groups
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21—Serine endopeptidases (3.4.21)
    • C12Y304/21021—Coagulation factor VIIa (3.4.21.21)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21—Serine endopeptidases (3.4.21)
    • C12Y304/21022—Coagulation factor IXa (3.4.21.22)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21—Serine endopeptidases (3.4.21)
    • C12Y304/21069—Protein C activated (3.4.21.69)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Hematology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Plant Pathology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

(57) Изобретение относится к витамин К-зависимым полипептидам с повышенной способностью связываться с мембраной. Указанные полипептиды могут использоваться для модуляции образования сгустка крови у млекопитающих. Описаны также способы модуляции образования сгустка крови у млекопитающих.Международная заявка была опубликована вместе с отчетом о международном поиске.
EA200000449A 1997-10-23 1998-10-20 Модифицированные витамины к-зависимые полипептиды EA200000449A1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/955,636 US6017882A (en) 1997-10-23 1997-10-23 Modified vitamin K-dependent polypeptides
PCT/US1998/022152 WO1999020767A1 (en) 1997-10-23 1998-10-20 Modified vitamin k-dependent polypeptides

Publications (1)

Publication Number Publication Date
EA200000449A1 true EA200000449A1 (ru) 2000-12-25

Family

ID=25497114

Family Applications (1)

Application Number Title Priority Date Filing Date
EA200000449A EA200000449A1 (ru) 1997-10-23 1998-10-20 Модифицированные витамины к-зависимые полипептиды

Country Status (30)

Country Link
US (1) US6017882A (ru)
EP (2) EP1676919B1 (ru)
JP (1) JP4276379B2 (ru)
KR (1) KR20010031370A (ru)
CN (1) CN1246462C (ru)
AP (1) AP2000001811A0 (ru)
AR (2) AR020048A1 (ru)
AT (1) ATE390486T1 (ru)
AU (1) AU749279C (ru)
BR (1) BR9814611A (ru)
CA (1) CA2307175C (ru)
DE (1) DE69839313T2 (ru)
DK (1) DK1090128T3 (ru)
EA (1) EA200000449A1 (ru)
ES (2) ES2303362T3 (ru)
HR (1) HRP20000234A2 (ru)
HU (1) HU225993B1 (ru)
ID (1) ID26330A (ru)
IL (1) IL135603A0 (ru)
IS (1) IS5449A (ru)
MY (1) MY136336A (ru)
NO (1) NO20002025L (ru)
NZ (1) NZ504114A (ru)
PL (1) PL194194B1 (ru)
PT (1) PT1090128E (ru)
SG (1) SG105547A1 (ru)
TR (1) TR200001105T2 (ru)
TW (1) TW587081B (ru)
WO (1) WO1999020767A1 (ru)
ZA (1) ZA989597B (ru)

Families Citing this family (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7247708B2 (en) 1997-10-23 2007-07-24 Regents Of The University Of Minnesota Modified vitamin K-dependent polypeptides
US6747003B1 (en) * 1997-10-23 2004-06-08 Regents Of The University Of Minnesota Modified vitamin K-dependent polypeptides
US6693075B1 (en) * 1997-10-23 2004-02-17 Regents Of The University Of Minnesota Modified vitamin K-dependent polypeptides
US6998122B1 (en) 1999-04-30 2006-02-14 Eli Lilly And Company Protein C derivatives
JP2003514545A (ja) * 1999-11-19 2003-04-22 イーライ・リリー・アンド・カンパニー プロテインｃ誘導体
EP1255821B1 (en) 2000-02-02 2004-12-29 Eli Lilly And Company Protein c derivatives
EP1263943A1 (en) 2000-02-11 2002-12-11 Eli Lilly & Company Protein c derivatives
DE60138364D1 (de) 2000-02-11 2009-05-28 Bayer Healthcare Llc Gerinnungsfaktor vii oder viia konjugate
US7220837B1 (en) 2000-04-28 2007-05-22 Regents Of The University Of Minnesota Modified vitamin K-dependent polypeptides
US7812132B2 (en) 2000-04-28 2010-10-12 Regents Of The University Of Minnesota Modified vitamin K-dependent polypeptides
US7160540B2 (en) * 2000-06-30 2007-01-09 Regents Of The University Of Minnesota Methods for detecting activity of clottings factors
US20030211094A1 (en) * 2001-06-26 2003-11-13 Nelsestuen Gary L. High molecular weight derivatives of vitamin k-dependent polypeptides
US6423826B1 (en) 2000-06-30 2002-07-23 Regents Of The University Of Minnesota High molecular weight derivatives of vitamin K-dependent polypeptides
WO2002009678A2 (en) * 2000-07-31 2002-02-07 Ottawa Heart Institute Research Corporation Charged phospholipid compositions and methods for their use
US6933367B2 (en) 2000-10-18 2005-08-23 Maxygen Aps Protein C or activated protein C-like molecules
WO2002070681A1 (en) * 2001-03-02 2002-09-12 T.A.C. Thrombosis And Coagulation Ab Protein c variants
CA2477876A1 (en) * 2002-03-01 2003-09-12 T.A.C. Thrombosis And Coagulation Aktiebolag Recombinant protein c variants
US20030186862A1 (en) * 2002-04-02 2003-10-02 Nelsestuen Gary L. Factor VIIa compositions
SI1499719T1 (sl) * 2002-04-30 2011-03-31 Bayer Healthcare Llc Polipeptidne variante faktorja VII ali VIIa
US20030232075A1 (en) * 2002-05-06 2003-12-18 University Of Minnesota, A Minnesota Corporation Compositions for producing factor Xa
EP1517698B2 (en) 2002-06-21 2017-12-06 Novo Nordisk Health Care AG STABILISED SOLID COMPOSITIONS OF FACTOR VIIa POLYPEPTIDES
US20040176704A1 (en) * 2003-03-04 2004-09-09 Stevens Timothy A Collection device adapted to accept cartridge for point of care system
CN101818138A (zh) 2003-03-18 2010-09-01 诺和诺德医疗保健公司 生产含有gla残基的丝氨酸蛋白酶的方法
WO2004083361A2 (en) * 2003-03-20 2004-09-30 Maxygen Holdings Ltd. FVII OR FVIIa VARIANTS
CA2529828C (en) * 2003-06-19 2013-01-15 Maxygen Holdings Ltd. Factor vii or viia gla domain variants
CN101870729A (zh) 2003-09-09 2010-10-27 诺和诺德医疗保健公司 凝固因子ⅶ多肽
KR100755967B1 (ko) * 2003-10-23 2007-09-06 한국타이어 주식회사 타이어의 비드와 휠의 갭 측정장치
JP4874806B2 (ja) 2003-12-01 2012-02-15 ノボ ノルディスク ヘルス ケア アクチェンゲゼルシャフト 液体因子ｖｉｉ組成物のウイルス濾過
EP2298287B1 (en) 2003-12-19 2018-04-11 Novo Nordisk Health Care AG Stabilised compositions of factor VII polypeptides
RU2385879C2 (ru) 2004-01-21 2010-04-10 Ново Нордиск Хелс Кеа Аг Способ конъюгации пептидов, опосредованной трансглутаминазой
BRPI0519626A2 (pt) 2004-12-23 2009-02-25 Novo Nordisk Healthcare Ag mÉtodos para a reduÇço do teor de um ou mais contaminantes, do teor de proteÍna s em uma composiÇço, do teor de um ou mais contaminantes de proteÍna em um sobrenadante de cultura de cÉlula, do teor de proteÍna s em um sobrenadante de cultura de cÉlula, composiÇço compreendendo uma proteÍna dependente de vitamina k de interesse
US8206750B2 (en) 2005-03-24 2012-06-26 Cerenis Therapeutics Holding S.A. Charged lipoprotein complexes and their uses
US20080188400A1 (en) * 2005-04-26 2008-08-07 Maxygen Holdings Ltd. Methods For Treating Bleeding
ES2553160T3 (es) 2005-06-17 2015-12-04 Novo Nordisk Health Care Ag Reducción y derivatización selectivas de proteínas Factor VII transformadas por ingeniería que comprenden al menos una cisteína no nativa
ES2397851T3 (es) 2005-07-13 2013-03-11 Novo Nordisk Health Care Ag Células de inactivación proteínica de la célula huésped para la producción de proteínas terapéuticas
ES2515915T3 (es) 2005-09-01 2014-10-30 Novo Nordisk Health Care Ag Purificación de los polipéptidos del Factor VII mediante cromatografía de interacción hidrofóbica
US20090055942A1 (en) 2005-09-14 2009-02-26 Novo Nordisk Healthcare A/G Human Coagulation Factor VII Polypeptides
ES2531934T3 (es) 2006-09-01 2015-03-20 Novo Nordisk Health Care Ag Glicoproteínas modificadas
CA2673260A1 (en) * 2006-12-20 2008-07-03 Bayer Healthcare Llc Factor vii and viia compositions
AU2008239586B2 (en) 2007-04-13 2013-09-26 Catalyst Biosciences, Inc. Modified factor VII polypetides and uses thereof
US20080305157A1 (en) * 2007-06-08 2008-12-11 University Of Maryland Office Of Technology Commercialization Encapsulation and separation of charged organic solutes inside catanionic vesicles
DK2235197T3 (en) 2007-12-27 2017-10-09 Baxalta GmbH Methods of cell culture
TWI465247B (zh) 2008-04-11 2014-12-21 Catalyst Biosciences Inc 經修飾的因子ｖｉｉ多肽和其用途
NO2440239T3 (ru) 2009-06-09 2018-02-10
WO2011074578A1 (ja) * 2009-12-14 2011-06-23 国立大学法人北海道大学 脂質膜構造体に細胞透過能を付与および／または脂質膜構造体の細胞透過能を増強するペプチド、ならびにそれらペプチドと結合した脂質を構成脂質として含む、細胞透過能を有するまたは細胞透過能が増強された脂質膜構造体
TWI595004B (zh) 2010-11-03 2017-08-11 介控生化科技公司 經修飾之第九因子多胜肽及其用途
IN2015DN01404A (ru) 2012-07-25 2015-07-03 Catalyst Biosciences Inc
US11491212B1 (en) 2017-09-27 2022-11-08 Catalyst Biosciences, Inc. Subcutaneous administration of modified factor IX polypeptides and treatment of hemophilia B
CN114728044A (zh) 2019-08-15 2022-07-08 介控生化科技公司 用于皮下施用和按需求治疗的经修饰的因子vii多肽
WO2021154414A2 (en) 2020-01-29 2021-08-05 Catalyst Biosciences, Inc. Gene therapy for hemophilia b with a chimeric aav capsid vector encoding modified factor ix polypeptides

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2799316B2 (ja) * 1987-06-12 1998-09-17 ヘキスト・マリオン・ルセル株式会社 雑種ヒトプロテインｃおよびその遺伝子工学的製法
JPH0246296A (ja) * 1988-08-09 1990-02-15 Hoechst Japan Ltd 雑種プロテインｃ及びその製造方法
US5580560A (en) * 1989-11-13 1996-12-03 Novo Nordisk A/S Modified factor VII/VIIa
EP0521873B1 (en) * 1990-01-29 1999-06-02 Zymogenetics, Inc. Anticoagulant proteins
US5504064A (en) * 1991-04-10 1996-04-02 Oklahoma Medical Research Foundation Treatment of bleeding with modified tissue factor in combination with an activator of FVII

Also Published As

Publication number Publication date
AR035786A2 (es) 2004-07-14
ZA989597B (en) 1999-04-23
HUP0102257A3 (en) 2003-09-29
US6017882A (en) 2000-01-25
HUP0102257A2 (hu) 2001-09-28
IL135603A0 (en) 2001-05-20
EP1676919B1 (en) 2014-07-23
AP2000001811A0 (en) 2000-06-30
HU225993B1 (en) 2008-02-28
JP2001520042A (ja) 2001-10-30
AR020048A1 (es) 2002-04-10
SG105547A1 (en) 2004-08-27
EP1676919A1 (en) 2006-07-05
AU749279B2 (en) 2002-06-20
ATE390486T1 (de) 2008-04-15
NZ504114A (en) 2002-10-25
DE69839313T2 (de) 2009-04-16
NO20002025D0 (no) 2000-04-18
AU2702499A (en) 1999-05-10
PL194194B1 (pl) 2007-05-31
AU749279C (en) 2004-09-16
TR200001105T2 (tr) 2000-09-21
MY136336A (en) 2008-09-30
ID26330A (id) 2000-12-14
EP1090128B1 (en) 2008-03-26
PT1090128E (pt) 2008-04-17
IS5449A (is) 2000-04-14
ES2496104T3 (es) 2014-09-18
HRP20000234A2 (en) 2001-08-31
NO20002025L (no) 2000-06-19
TW587081B (en) 2004-05-11
CN1283231A (zh) 2001-02-07
BR9814611A (pt) 2000-10-03
EP1090128A1 (en) 2001-04-11
KR20010031370A (ko) 2001-04-16
CA2307175C (en) 2009-04-14
CN1246462C (zh) 2006-03-22
ES2303362T3 (es) 2008-08-01
JP4276379B2 (ja) 2009-06-10
PL340284A1 (en) 2001-01-29
DE69839313D1 (de) 2008-05-08
DK1090128T3 (da) 2008-06-23
WO1999020767A1 (en) 1999-04-29
CA2307175A1 (en) 1999-04-29

Similar Documents

Publication Publication Date Title
EA200000449A1 (ru) Модифицированные витамины к-зависимые полипептиды
DE60045752D1 (de) Modifizierte Faktor-VIIA-Polypeptide
DK0654078T3 (da) Thrombinblodfraktion til anvendelse i en medicinsk procedure
EA199900381A1 (ru) Арил(тио)эфиры галогенпиримидина в качестве пестицидов
ATE339507T1 (de) Erythropoietin-analog-menschliches serum-albumin fusionsprotein
EA199800946A1 (ru) Концентрированный препарат антител
DE69729786D1 (de) Hochkonzentrierte, lyophilisierte und flüssige faktor-ix formulierungen
EA199800667A1 (ru) Новые фенантридины
ES2084702T3 (es) Imidazoles sustituidos utiles como inhibidores de la angiotensina ii.
EA199801044A1 (ru) Модуляторы регенерации тканей
PT975359E (pt) Potencializacao da resposta imunitaria atraves de distribuicao de compostos que se ligam a uma dipeptidase citoplasmatica
ATE250625T1 (de) IM WESENTLICHEN REINES ZONULIN ALS PHYSIOLOGISCHER MODULATOR VON ßTIGHT JUNCTIONSß BEI SÄUGERN
DE3382837D1 (de) Herstellung von funktionellen, menschlichen Urokinaseproteinen
TR199900903T2 (xx) Bir t�m�r nekroz fakt�r� ailesine ili�kin protein
DE58906338D1 (de) Kombination von Angiotensin-Converting-Enzyme-Hemmern mit Kaliumkanal-Modulatoren sowie deren Verwendung in Arzneimitteln.
AR009819A1 (es) Inhibidores de la proteasa proteinicos estabilizados y sus variantes
DK0939769T3 (da) Vertebrat-Smoothened-proteiner
DE69929683D1 (de) Antisense modulierung von lfa-3
ATE40116T1 (de) 1-acyl-3-pyridylmethylguanidine und deren verwendung als antihypertensiva.
DE60042273D1 (de) Antitumorantikörper, proteine und deren verwendung
ATE389014T1 (de) Phosphorylierte glyoxalase i und deren verwendung
EA200200321A1 (ru) Апоптин-ассоциированный белок
EA200100110A1 (ru) Нейротрофические факторы
EA199800028A1 (ru) Винилсульфоксиды и способы их синтеза
AR010620A4 (es) Jeringa autodescartable grima